Cytokines and cell regulation

Molecular Aspects of Medicine

Volumn 18, Issue 1, 1997, Pages 1-90

  Fridman, Wolf H ^a   Tartour, Eric ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR;

CANCER; CYTOLOGY; GENE; HUMAN; IMMUNOSTIMULATION; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS REGULATION; REVIEW; ANIMAL; ANTIBODY PRODUCTION; ARTHRITIS; ENTERITIS; HELPER CELL; IMMUNE SYSTEM; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MOUSE MUTANT;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS; CYTOKINES; DIABETES MELLITUS, TYPE 1; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, MUTANT STRAINS; RECEPTORS, CYTOKINE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0031067579     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0098-2997(96)00012-X     Document Type: Review

References (285)

1. Aarden, L. A., Brunner, T. K. and Cerottini, J. C. (1979). Revised nomenclature for antigen-non specific T cell proliferation and helper factors. J. Immunol. 123, 2928-2929.
2. Aderka, D., Engelmann, H., Hornik, V., Skornick, Y., Levo, Y., Wallach, D. and Kushtar, G. (1991). Increased serum levels of soluble receptors for tumour necrosis factor in cancer patients. Cancer Res. 51, 5602.
3. Aderka, D., Engelmann, H., Maor, Y., Brakebusch, C. and Wallach, D. (1992). Stabilization of the bioactivity of tumour necrosis factor by its soluble receptors. J. Exp. Med. 175, 323.
4. Aderka, D., Wysenbeek, A. and Engelmann, H. (1993). Correlation between serum levels of soluble tumour necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 36, 1111.
5. Alcami, A. and Smith, G.L. (1992). A soluble receptor for interleukin 10 encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153.
6. Alcami, A. and Smith, G.L. (1995). Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Immunol. Today 16, 474.
7. Alexander, H.R., Doherty, G.M., Buresch, C.M., Venzon, D.J. and Norton, J.A. (1991). A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxinemia in mice. J. Exp. Med. 173, 1029.
8. Amigorena, S., Bonnerot, C., Fridman, W.H. and Teillaud, J.L. (1990). Recombinant interleukin-2 activated natural killer cells regulate IgG2α production. Eur. J. Immunol. 20, 1781.
9. Anegon, L., Cuturi, M.C., Trinchieri, G. and Perussia, B. (1988). Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167, 452.
10. Arend, W. P. and Dayer, J. M. (1994). Naturally occurring inhibitors of cytokines. In Immunopharmacology of Joints and Connective Tissue, Davies, M. E., Dingle, J. T. Eds. Academic Press, London, p. 129.
11. Armitage, R.J. (1994). Tumor necrosis factor receptor superfamiliy members and their ligands. Curr. Opin. in immunol. 6, 407.
12. Arrick, B.A., Lopez, A.R., Elfman, F., Ebener, R., Damsky, C.H. and Derynck, R. (1992). Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell. Biol. 118, 715-726.
13. Atkins, M.B., O'Boyle, K.R., Sosman, J.A., Weiss, G.R., Margolin, K.A., Ernest, M.L., Kappler, K., Mier, J.W., Sparano, J.A. and Fisher, R.I. (1994). Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol. 12, 1553-1560.
14. Atzpodien, J., Körfer, A., Franks, C.R., Poliwoda, H. and Kirchner, H. (1990). Home therapy with recombinant interleukin 2 and interferon -α2b in advanced human malignancies. Lancet 335, 1509-1512.
15. Balavoine, J.F., de Rochemonteix, B., Williamson, K., Seckinger, P., Cruchaud, A. and Dayer, J.M. (1986). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by udne-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78, 1120.
16. Barral-Netto, M., Barral, A., Santos, S.B., Carvalho, E.M., Badaro, R., Rocha, H., Reed, S.G. and Johnson, W.D. Jr. (1991). Soluble IL-2 receptor as an agent of serum mediated suppression in human visceral Leishmaniasis. J. Immunol. 147, 281.
17. Bast, R.C. Jr., Boyer, C.M., Jacobs, I., Xu, F.J., Wu, S., Wiener, J., Kohler, M. and Berchuck, A. (1993). Cell growth regulation in epithelial ovarian cancer. Cancer 71, 1597-1601.
18. Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. and Klein, B. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685-691.
19. Beutler, B., Milsark, I.W. and Cerami, A. (1985). Passive immunization against cachectin/ tumour necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869.
20. Blackwell, T.K. and Alt, F.W. (1989). Mechanism and developmental program of immunoglobulin gene rearrangement in mammals. Annu. Rev. Genet. 23, 605.
21. Blay, J.Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J. and Favrot, M. (1993). Serum interleukin 10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82, 2169.
22. Blay, J.Y., Favrot, M., Rossi, J.F. and Wijdenes, J. (1993). Role of interleukin 6 in paraneoplastic thrombocytosis. Blood 87, 2261-2262.
23. Blay, J.Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Mezrrouche, Y., Mercatello, A., Ravault, A., Tourani, J.M., Moskovtchenko, J.F., Philip, T. and Favrot, M. (1992). Serum levels of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52, 3317.
24. Bloom, B.R. and Bennett, B. (1966). Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153, 80-82.
25. Borsellino, N., Belldegrun, A. and Bonavida, B. (1995). Endogenous interleukin 6 is a resistance factor for cis Diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55, 4633-4639.
26. Brunda, M.J., Luistro, L., Warrier, R.R., Wright, R.B., Hubbard, B.R. and Murphy, M. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230.
27. Burdin, N., Van Kooten, C., Galibert, L., Abrams, J.S., Wijdenes, J., Banchereau, J. and Rousset, F. (1995). Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J. Immunol. 154, 2533-2544.
28. Campbell, I.L., Hobbs, M.V., Dockter, J., Oldstone, M.B. and Allison, J. (1994). Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Amer. J. Pathol. 145, 157.
29. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N. and Williamson, B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72, 3666-3670.
30. Chen, T., Tao, M.H. and Levy, R. (1995). Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153, 4775-4787.
31. Chen, L., Mory, Y., Zilberstein, A. and Revel, M. (1988). Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc. Nat. Acad. Sci. 85, 8037-8041.
32. Chilosi, M., Semenzato, G., Cetto, G., Ambrosetti, A., Fiore-Donati, L., Perona, G., Berton, G., Lestani, M., Scarpa, A., Agostini, C., Trentin, L., Zambello, R., Masciarelli, M., Dazzi, F., Vinante, F., Caligaris-Cappio, F. and Pizzolo, G. (1987). Soluble interleukin 2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 70, 1530.
33. Cimoli, G., Russo, P., Billi, G., Mariani, G.L., Rovini, E. and Venturini, M. (1991). Human granulocyte-macrophage colony-stimulating factor is a growth factor active on human ovarian cancer cells. J. Cancer Res. 82, 1196-1198.
34. Cockayne, D.A., Bodine, D.M., Cline, A., Nienhuis, A.W., Dunbar, C.E. (1994). Transgenic mice expressing antisense interleukin-3 RNA develop a B-cell lymphoproliferative syndrome or neurologic dysfunction. Blood 84, 2699.
35. Cohen, S., Bigazzi, P.E. and Yoshida, T. (1974). Similarities of T cell function in cell-mediated immunity and antibody production. Cell. Immunol. 12, 150-159.
36. Cope, A.P., Londei, M., Chu, N.R., Cohen, S.B., Elliott, M.J., Brennan, F.M., Maini, R.N. and Feldmann, R. (1994). Chronic exposure to tumour necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94, 749.
37. Daëron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S. and Fridman, W.H. (1995). The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3, 635-646.
38. Danforth, D.N. Jr. and Sgagias, M.K. (1993). Interleukin 1 alpha and interleukin 6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res. 53, 1538-1545.
39. David, J.R. (1966). Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U.S. A 56, 72-77.
40. Davis, M.M. and Bjorkman, P.J. (1988). T-cell antigen receptor genes and T-cell recognition. Nature 334, 395.
41. Davis, S., Aldrich, T.H., Stahl, N., Pan, L., Taga, T., Kishimoto, T., Ip, N.Y. and Yancopoulos, G.D. (1993). LIFRβ and gp130 as heterodimeziring signal transducers of the tripartite CNTF receptor. Science 260, 1805.
42. Dayer, J.M. and Burger, D. (1994). Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw, 5, 563-571.
43. Dayer, J.M. and Fenner, H. (1992). The role of cytokines and their inhibitors in arthritis. Baillieres-Clin-Rheumatol. 6, 485.
44. De Maeyer-Guignard, J., Tovey, M.G., Gresser, I. and de Maeyer, E. (1978). Purification of mouse interferon by sequential affinity chromatography on poly (U)-and antibody-agarose colums. Nature 271, 622-625.
45. De Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C.G. and De Vries, J.E. (1991). Interleukin 10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL10 produced by monocytes. J. Exp. Med. 174, 1209.
46. Desai, B.B., Quinn, P.M., Wolitzky, A.G., Mongini, P.K., Chizzonite, R. and Gately, M.K. (1992). IL12 receptor. II Distribution and regulation of receptor expression. J. Immunol. 148, 3125-3132.
47. Digel, W., Porzsolt, F., Schmid, M., Herrmann, F., Lesslauer, W. and Brockhaus, M. (1992). High levels of circulating soluble receptors for tumour necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J. Clin. Invest. 89, 1690.
48. Dinarello, C.A. (1994). The biological properties of interleukin-1. Eur. Cytokine Netw. 5, 517-531.
49. Dinarello, C.A., Gelfand, J.A. and Wolff, S.M. (1993). Anti-cytokine strategies in the treatment of the systemic inflammatory response syndrome. Jama 269, 1829.
50. Dinarello, C.A., Renfer, L. and Wolff, S.M. (1977). Human leukoeytic pyrogen: purification and development of a radioimmuno assay. Proc. Natl. Acad. Sci. U.S.A. 74, 4624.
51. Dorval, T., Negrier, S., Chevreau, C., Baume, D., Cupissol, D., Oskam, R., De Peuter, M.A., Herrera, A. and Escudier, B. (1994). Results of a french multicentric randomized trial of chemoimmunotherapy. Proc. Am. As. Soc. Clin. oncol. 13, 395.
52. Dower, S.K. and Urdal, D.L. (1987). The interleukin-1 receptor. Immunol. Today 8, 46.
53. Dumonde, D.C., Wolstencroft, R.A., Panayi, G.S., Matthew, M., Morley, J. and Howson, W.T. (1969). Lymphokines: non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature 224, 38-40.
54. Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., MacFarlane, J.D., Bijl, H. and Woody, J.N. (1994a). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105.
55. Elliott, M.J., Maini, R.N., Feldmann, M., Long Fox, A., Charles, P., Bijl, H. and Woody, J.N. (1994b). Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125.
56. Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F.M., Walker, J., Bijl, H. and Ghrayeb, J. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681.
57. Engelberts, I., Stephens, S., Francot, G.J.M., van der Linden, C.J. and Buurman, W.A. (1991). Evidence for different effects of soluble TNF receptors on various TNF measurements in human biological fluids. Lancet 338, 515.
58. Ernst, M., Gearing, D.P. and Dunn, A.R. (1994). Functional and biochemical association of Hck with the LIF/IL6 receptor signal transducing subunit gp130 in embryonic stem cells. Embo. J. 13, 1574-1584.
59. Erroi, A., Sironi, M., Chiaffarino, F., Guo, C.Z., Mengozzi, M. and Mantiovani, A. (1989). IL1 and IL6 release by tumor associated macrophages from human ovarian carcinoma. Int. J. Cancer. 44, 795-801.
60. Fanslow, W.C., Sims, J.E., Sassenfield, H., Morrissey, P.J., Gillis, S., Dower, S.K. and Widmer, M.B. (1990). Regulation of alloreactivity in vivo by a soluble form of interleukin-1 receptor. Science 248, 739.
61. Farrar, W.L., Hill, J.M., Harel-Bellan, A. and Vinocour, M. (1987). The immune logical brain. Immunol. Rev. 100, 361-378.
62. Fattori, E., Della Rocca, C., Costa, P., Giorgino, M., Dente, B., Pozzi, L. and Ciliberto, G. (1994). Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83, 2570.
63. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbeck, P., Levitsky, H.I., Simons, J.W., Darasuyama, H., Vogelstein, B. and Frost, P. (1990). Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397.
64. Fernandez Botran, R. and Vitetta, E.S. (1990). A soluble high affinity-interleukin 4 binding protein is present in biological fluids of mice. Proc. Nat. Acad. Sci. 87, 202.
65. Finkelman, F.D. and Holmes, J. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 803-833.
66. Finkelman, F.D., Madden, K.B., Mords, S.C., Holmes, J.M., Boaini, N., Katona, I.M. and Maliszewski, C.R. (1993). Anti-Cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-Anti-cytokine antibody complexes. J. Immunol. 151, 1235.
67. Fisher, A. and Leonard, W.J. (1995). Inherited immunodeficiencies. The Immunologist 3, 237-240.
68. Fomsgaard, A., Svenson, M. and Bendtzen, K. (1989). Auto-antibodies to tumour necrosis factor a in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand. J. Immunol. 30, 219.
69. Fridman, W.H. (1991). Le cerveau mobile. De l'immunité au système immunitaire. Eds Hermann.
70. Fridman, W.H. and Golstein, P. (1974). Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cellular Immunol. 11, 442-455.
71. Galve de Rochemonteix, B., Dayer, J.M. and Junod, A.F. (1990). Fibroblast-alveolar cell interactions in sarcoidosis and idiopathic pulmonary fibrosis: evidence for stimulatory and inhibitory cytokine production by alveolar cells. Eur. Respir. J. 3, 653.
72. Gatanaga, T.C., Hwang, C., Kohr, W., Cappuccini, F., Lucci, J.A., Jeffes, E.W.B., Lentz, R., Tomich, J., Yamamoto, R.S. and Granger, G.A. (1990). Purification and characterization of an inhibitor (soluble tumour necrosis factor receptor) for tumour necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci. USA 87, 8781.
73. Gearing, A.J.H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A.H., Drummond, A.H., Galloway, W.A., Gilbert, R., Gordon, J.L., Leber, T.M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, W., Thomas, W., Wells, G., Wood, L.M. and Woolley, K. (1994). Processing of tumour necrosis factor-α precursor by mettalloproteinases. Nature 370, 55.
74. Gery, I. and Waksman, B.H. (1972). Potential of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J. Exp. Med. 136, 143-155.
75. Gillis, S. and Smith, K. (1977). Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154.
76. Girardin, E., Roux-Lombard, P., Grau, G.E., Suter, P., Gallati, H., The J5 study group, Dayer, J.M. (1992). Imbalance between tumour necrosis factor and soluble TNF receptor level in severe meningococcemia. Immunology 76, 20.
77. Golumbek, P., Azhari, R., Jaffee, E.M., Levitsky, H.I., Lazenby, A., Leong, K. and Pardoll, D. (1993). Controlled release biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53, 5841-5844.
78. Golumbek, P., Lazenby, A., Levitsky, H., Jaffee, E., Karasuyama, H., Kaker, M. and Pardoll, D. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
79. Gordon, J. and MacLean, L.D. (1965). A lymphocyte-stimulating factor produced in vitro. Nature 208, 795-796.
80. Grabstein, K.H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung,. V., Beers, C., Richardson, J., Schoenborn, M.A., Ahdieh, M., Johnson, L., Alderson, M.R., Watson, J.D., Anderson, D.M. and Girl, J.G. (1994). Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264, 965.
81. Granger, G.A., Shacks, S.J., Williams, T.W. and Kold, W.P. (1969). Lymphocyte in vitro cytotoxicity: specific release of lymphotoxin-like materials from tuberculin-sensitive lymphoid cells. Nature 221, 1155-1157.
82. Green, S.J., Nacy, M.S. and Meltzer, M.S. (1991). Cytokine induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J. Leuk. Biol. 50, 93.
83. Greenberg, A.S., Nordan, R.P., McIntosh, J., Calvo, J.C., Scow, R.O. and Jablons, D. (1992). Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52, 4113-4116.
84. Grell, M., Douni, E., Wajant, H., Lönden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pilzenmaier, K. and Scheurich, P. (1995). The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802.
85. Gresser, I. (1977). On the varied biologic effects of interferon. Cell. Immunol. 34, 406415.
86. Grimm, E.A., Mazumder, A., Zhang, H.Z. and Rosenberg, S.A. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumour cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823.
87. Hercus, T.R., Bagley, C.J., Cambareri, B., Dottore, M., Woodcock, J.M., Vadas, M.A., Shannon, M.F. and Lopez, A.F. (1994). Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc. Natl. Acad. Sci. USA 91, 5838.
88. Herrmann, F., Helfrich, S.G., Lindemann, A., Schleiermacher, E., Huber, C. and Merstelmann, R. (1992). Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J. Clin. Oncol. 10, 631.
89. Hiscox, S., Hallett, M.B., Puntis, M.C. and Jiang, W.G. (1995). Inhibition of cancer cell motility and invasion by interleukin 12. Clin. Exp. Metast. 5, 396-404.
90. Honda, M., Kitamura, K. and Mutsuda, K. (1989). Soluble IL2 receptor in AIDS. Correlation of its serum level with the classification of HIV induced diseases and its characterization. J. Immunol. 142, 42-48.
91. Horak, I. (1995). Immunodeficiency in IL-2 deficient mice. Clin. Immunol. Immunopathol. 76, S172-173.
92. Hsu, M.M., Ko, J.Y. and Chang, Y.L. (1991). Elevated levels of soluble interleukin 2 receptor and tumor necrosis factor in nasopharyngeal carcinoma. Arch. Otol. Head Neck Surg. 117, 1257.
93. Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, R., Kamijo, R., Vilcek, R.M., Zinkernagel, R.M. and Aguet, M. (1993). Immune response in mice that lack the interferon-γ receptor. Science 259, 1742.
94. Hullet, M.D. and Hogarth, P.M. (1994). Molecular basis of Fc receptor Function. Advances Immunol. 57, 1-127.
95. Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K. and Silvennoinen, O. (1995). Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13, 369.
96. Ivashkiv, L.B. (1995). Cytokines and STATs: how can signals achieve specificity? Immunity 3, 1-4.
97. Kasakura, S. and Lowenstein, L. (1965). A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. Nature 208, 794-795.
98. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kousis, D. and Kollias, G. (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model. Embo. J. 10, 4025.
99. Keller, U. (1993). Pathophysiology of cancer cachexia. Supportive care in cancer 6, 290-294.
100. Kestler, D.P., Agarwal, S., Cobb, J., Goldstein, K.M. and Hall, R.E. (1995). Detection and analysis of an alternatively spliced isoform of interleukin 6 mRNA in peripheral blood mononuclear cells. Blood 86, 4559-4567.
101. Khayat, D., Borel, C., Tourani, J.M., Benhammouda, A., Antoine, E., Rixe, O., Vuillemin, E., Bazex, P.A., Thill, L., Franks, R., Auclerc, G., Soubrane, C., Banzet, P. and Weil, M. (1993). Sequential chemoimmunotherapy with cisplatin interleukin 2 and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol. 11, 2173-2180.
102. Kirkwood, J.M. (1996). Biological therapy of melanoma. Proc. Amer. Assoc. Cancer Res. 37, 641.
103. Kishimoto, T. (1989). The biology of interleukin 6. Blood 74, 1-10.
104. Kishimoto, T., Akira, S. and Taga, T. (1992). Interleukin 6 and its receptor: a paradigm for cytokines. Science 258, 593-597.
105. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. (1995). Interleukin-6 family of cytokines and gp130. Blood 86, 1243.
106. Kishimoto, T., Taga, T. and Akira, S. (1994). Cytokine signal transduction. Cell 76, 253.
107. Kitamura, T., Sato, N., Arai, K. and Miyajima, A. (1991). Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 66, 1165.
108. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. and Bataille, R. (1989). Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin 6. Blood 73, 517-526.
109. Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H. and Köhler, G. (1994). Impaired immune and acute-phase responses in interleukin-6 deficient mice. Nature 368, 339.
110. Kopf, M., Le Gros, G., Bachmann, M., Lamers, M.C., Bluethmann, H. and Köhler, G. (1993). Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362, 245.
111. Krasagakis, K., Garbe, C., Zouboulis, C.C. and Orfanos, C.E. (1995). Growth control of melanoma cells and melanocytes by cytokines. Recent Results in Cancer Res. 139, 169-182.
112. Kühn, R., Löhler, J., Rennick, D., Rajewsky, K. and Müller, W. (1993). Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75, 263.
113. Kühn, R., Rajewsky, K. and Müller, W. (1991). Generation and analysis of interleukin 4 deficient mice. Science 254, 707-710.
114. Kuida, K., Lippke, J.A., Ku, G., Harding, M.W., Livingston, D.J., Su, M.S. and Flavell, R.A. (1995). Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 267, 2000-2003.
115. c subunit in signal transduction reveals functional asymmetry within multimetric cytokine receptor complexes. Proc. Natl. Acad. Sci. USA 93, 231.
116. Lantz, M., Gullberg, U., Nilsson, E. and Olsson, I. (1990). Characterization in vitro of a human tumour necrosis factor-binding protein. J. Clin. Invest, 86, 1396.
117. Lantz, M., Malik, S., Slevin, M.L. and Olsson, I. (1992). Infusion of tumour necrosis factor causes an increase in circulating TNF binding protein in human. Cytokine 2, 402.
118. Latour, S., Bonnerot, C., Fridman, W.H. and Daëron, M. (1992). Induction of tumor necrosis factor-α production by mast cells via FcγR: Role of the FcγRIII γ subunit. J. Immunol. 149, 2155-2162.
119. Lebsack, M.E., Paul, C.C., Marindale, J.J. and Catalano, M.A. (1993). A dose and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 36, S39.
120. Lee, M.S., Wogensen, L., Shizuru, J., Oldstone, M.B. and Sarvetnick, N. (1994). Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J. Clin. Invest. 93, 1332.
121. Leonard, W.J. (1994). The defective gene in X-linked severe combined immunodeficiency encodes a shared interleukin receptor subunit: implications for cytokine pleiotropy and redundancy. Curr. Opin. Immunol. 6, 631.
122. c. Immunol. Rev. 138, 59.
123. Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., Towne, E., Tracey, D., Wardwell, S., Wei, F.Y., Wong, W., Kamen, R. and Seshadri, T. (1995). Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80, 401-411.
124. Lin, J.X., Migone, T.S., Tsang, M., Friedmann, M., Weatherbee, J.A., Zhou, L., Yamauchi, A., Bloom, E.T., Mietz, J., John, S. and Leonard, W.J. (1995). The role of shared receptor motifs and common stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-15. Immunity 2, 331.
125. Lippman, S.M., Parkinson, D.R., Itri, L.M., Weber, R.S., Stimson, P., Schantz, S.P., Ota, D.M., Schusterman, M.A., Krakoff, I.H., Gutterman, J. and Ki Hong, W. (1992). 13 cis retinoic acid and Interferon alpha-2a. Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Nat. Cancer. Instit. 84, 235-241.
126. Loetscher, H., Gentz, R., Zulauf, M., Lustig, A., Tabuchi, H., Schlaeger, E.J., Brockhaus, M., Gallati, H., Manneberg, M. and Lesslauer (1991). Recombinant 55-kDa tumor necrosis factor receptor. Stoichiometry of binding to TNF α and TNF β and inhibition of TNF activity. J. Biol. Chem. 266, 18324.
127. Loetscher, H., Pan, Y.-C.E., Lahm, H.W., Gentz, R., Brockhaus, M., Tabuchi, H. and Lesslauer, W. (1990). Molecular cloning and expression of the human 55kD tumor necrosis factor receptor. Cell 61, 351.
128. Lopez, A.F., Vadas, M.A., Woodcock, J.M., Milton, S.E., Lewis, A., Elliott, M.J., Gillis, D., Ireland, R., Olwell, B. and Park, L.S. (1991). Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. J. Biol. Chem. 266, 24741.
129. Lotze, M.T., Rubin, J.T., Carty, S., Edington, H., Person, P., Landreneau, R., Pippin, B., Posner, M., Rosenfelder, D. and Watson, C. (1994). Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human gene Ther. 5, 41-55.
130. Lowenstein, L. and Bain, B. (1996). Blastogenesis in vitro and histocompatibility. Vox Sang 11, 305.
131. Lu, C. and Kerbel, R.S. (1993). Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol. 120, 1281-1288.
132. Lu, C., Vickers, M.F. and Kerbel, R.S. (1992). Interleukin 6: a fibroblast derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Nat. Acad. Sci. 89, 9215-9219.
133. Lüscher, U., Filgueira, L., Juretic, A., Zuber, M., Lüscher, N.J., Heberer, M. and Spagnoli, G. (1994). The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer. 57, 612.
134. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A. and Maffile, N.J. (1992). Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4, 96.
135. Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., Ugazio, A.G., Johnston, J.A., Candotti, F., O'Shea, J.J., Vezzoni, P. and Notarangelo, L.D. (1995). Mutations of jack-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65.
136. Magilavy, D.B., Fitch, F.W. and Gajewski, T.F. (1989). Murine hepatic accessory cells support the proliferation of TH1 but not TH2 helper T lymphocyte clones. J. Exp. Med 170, 985-990.
137. Manoussakis, M.N., Papadopoulos, G.J., Drosos, A.A. and Moutsopoulos, H.M. (1989). Soluble interleukin-2 receptor molecules in the serum of patients with autoimmune diseases. Clin. Immunol. Immunopathol. 50, 321.
138. Marincola, F.M., Withe, D.E., Wise, A.P. and Rosenberg, S.A. (1995). Combination therapy with interferon alpha-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13, 1110-1122.
139. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q.J., Masucci, M.G. and Kiessling, R, (1994). Interleukin 10 pretreatment protects target cells from tumor and allospecific cytotoxic T cells and down regulates HLA class I expression. J. Exp. Med. 180, 2371.
140. Matthews, D.J., Clark, P.A., Herbert, J., Morgan, G., Armitage, R.J., Kinnon, C., Minty, A., Grabstein, K.H., Caput, D., Ferrara, P. and Callard, R. (1995). Function of the interleukin-2 (IL-2) receptor γ-chain in biologic responses of x-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood 85, 38.
141. McGeehan, G.M., Becherer, J.D., Bast, R.C. Jr., Boyer, C.M., Champion, B., Connolly, K.M., Conway, J.G., Furdon, P., Karp, S., Kidao, S., McElroy, A.B., Nichols, J., Pryzwansky, K.M., Schoenen, F., Sekut, L., Truesdale, A., Verghese, M., Warner, J. and Ways, J.P. (1994). Regulation of tumour necrosis factor-α processing by a mettaloproteinase inhibitor. Nature 370, 558.
142. Meraz, M.A., White, J.M., Sheehan, K., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., Carver-Moore, K., DuBois, R.N., Clark, R., Aguet, M. and Schreiber, R.D. (1996). Targeted disruption of the stat 1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431.
143. Merluzzi, V.J., Welte, K. and Savage, D.M. (1983). Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J. Immunol. 131, 806.
144. Meyers, F.J., Gumerlock, P.H., Kawasaki, E.S., Wang, A.M., deVere White, R.W. and Erlich, H.A. (1991). Bladder cancer: human leukocyte antigen II, interleukin 6 and interleukin 6 receptor expression determined by the polymerase chain reaction. Cancer 67, 2087.
145. Meyskens, F.L. Jr., Kopecky, K.J., Taylor, C.W., Noyes, R.D., Tuthill, R.J., Hersh, E.M., Feun, L.G., Doroshow, J.H., Flaherty, L.E. and Sondak, V.K. (1995). Randomized trial of adjuvant human interferon gamma versus observation in high risk cutaneous melanoma: a southwest oncology group study. J. Nat. Cancer. Inst. 87, 1710-1712.
146. Mihara, M., Koishihara, Y., Fukui, H., Yasukawa, K. and Ohsugi, Y. (1991). Murine antihuman IL6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74, 55.
147. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T. and Kishimoto, T. (1989). IL6 functions as an autocrine growth factor in renal cell carcinoma. FEBS lett 250, 607-610.
148. Miles, D.W., Aderka, D., Engelmann, H., Wallach, D. and Balkwill, F.R. (1992). Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br. J. Cancer 66, 1195.
149. Miles, S.A., Rezai, A.R. and Salazar-Gonzalez, J.F. (1990). AIDS Kaposi sarcoma derived cells produce and respond to interleukin-6. Proc. Natl. Acad. Sci. USA 87, 4068.
150. Miller, L.C., Lynch, E.A., Isa, S., Logan, J.W., Dinarello, C.A. and Steere, A.C. (1993). Balance of synovial fluid IL1β and IL1 receptor antagonist and recovery from Lyme arthritis. Lancet 341, 146.
151. Minasian, L.M., Motzer, R.J., Gluck, L., Mazumdar, M., Vlamis; V. and Krown, S.E. (1993). Interferon alpha-2a in advanced renal cell carcinoma. Treatment results and survival in 159 patients with long term follow up. J. Clin. Oncol. 11, 1368-1375.
152. Mizutami, Y., Bonavida, B. and Koishihara, Y. (1995). Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 moniclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 55, 590-596.
153. Mohler, K.M., Sleath, P.R., Fitzner, J.N., Cerretti, D.P., Alderson, M., Kerwar, S.S., Torrance, D.S., Otten-Evans, C., Greenstreet, T., Weerawarna, K., Kronheim, S.R., Petersen, M., Gerhart, M., Kozlosky, C.J., March, C.J. and Black, R.A. (1994). Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370, 218.
154. Mohler, K.M., Torrance, D.S., Smith, C.A., Goodwin, R.G., Stremler, K.E., Fung, V.P., Madani, H. and Widmer, M.B. (1993). Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxinemia and function simultaneously as both TN-F carriers and TNF antagonists. J. Immunol. 151, 1548.
155. Mombaerts, P., Mizoguchi, E., Grusby, M.J., Glimcher, L.H., Bhan, A.K. and Tonegawa, S. (1993). Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75, 274-282.
156. Morgan, D.A., Tuscetti, F.W. and Gallo, R. (1976). Selective in vitro growth of T lympho-cytes from normal human bone marrow. Science 193, 1007-1008.
157. Morstyn, G. and Burgess, A.W. (1988). Hemopoietic growth factors: a review. Cancer Res. 48, 5624-5637.
158. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A. and Coffman, R.L. (1986). Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
159. Motzer, R.J., Schwartz, L., Murray, L.T., Murphy, B.A., Hoffman, A.D., Albino, A.P., Vlamis, V. and Nanus, M.D. (1995). Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J. Clin. Oncol. 13, 1950-1957.
160. Mule, J.J., Yang, J.C. and Lafreniere, R. (1987). Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin 2. J. Immunol. 139, 285.
161. Mule, J.J., McIntosh, J.K., Jablons, D.M. and Rosenberg, S.A. (1990). Antitumor activity of recombinant interleukin 6. in mice. J. Exp. Med. 171, 629.
162. Müllberg, J., Schooltink, H., Stoyan, T., Günther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P.C. and Rose-John, S. (1993). The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23, 473.
163. Muller, W. (1995). Dissecting the cytokine network. The Immunologist 3, 216-219.
164. Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T. and Kishimoto, T. (1993). IL-6 induced homodimerization of gp130 and associated activation of tyrosine kinase. Science 260, 1808.
165. Murphy, P.A., Chesney, P.A. and Wood, W.B. Jr. (1974). Further purification of rabbit leukocyte pyrogen. J. Lab. Clin. Med. 83, 310.
166. Nakagomi, H., Pisa, P., Pisa, E.K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C. and Kiessling, R. (1995). Lack of interleukin 2 (IL2) expression and selective expression of IL10 mRNA in human renal cell carcinoma. Int. J. Cancer. 63, 366-371.
167. Nakazaki, H. (1992). Preoperative and postoperative cytokines in patients with cancer. Cancer 70, 709.
168. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G.D., Taga, T. and Kishimoto, T. (1993). Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82, 1220.
169. Nastala, C.L., Edington, H.D., McKinney, T.G., Tahara, H., Nalesnik, M.A. and Brunda, M.J. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN gamma production. J. Immunol. 153, 1697-1706.
170. Noguchi, Y., Richards, E, Chen, Y.T. and Old, L.J. (1995). Influence of interleukin 12 on p53 peptide vaccination against established meth A sarcoma. Proc. Natl. Acad. Sci. 92, 2219-2223.
171. Noguchi, M., Yi, H., Rosenblatt, H.M., Filipovich, A.H., Adelstein, S., Modi, W.S., McBride, O.W. and Leonard, W.J. (1993). Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147.
172. Novick, D., Cohen, B. and Rubinstein, M. (1994). The human interferon α/β receptor characterization and molecular cloning. Cell 77, 391.
173. Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R. and Thompson, R.C. (1990). Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature 348, 550.
174. Oka, Y., Rolink, A.G., Suematsu, S., Kishimoto, T. and Melchers, F. (1995). An interleukin-6 transgene expressed in B lymphocyte lineage cells overcomes the T cell-dependent establishment of normal levels of switched immunoglobulin isotypes. Eur. J. Immunol. 25, 1332.
175. Okamoto, T., Watanabe, N., Yamauchi, N., Tsuji, Y., Tsuji, N., Itoh, Y., Neda, H. and Niitsu, Y. (1992). Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res. 52, 5278-5281.
176. Olcese, L., Lang, R., Vély, R., Cambiaggi, A., Marguet, D., Bléry, M., Hippen, K. L., Biassoni, R., Moretta, A., Moretta, L., Cambier, J. C. and Vivier, E. (1996). Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J. Immunol. 156, 4531-4534.
177. Pandiella, A. and Massague, J. (1991). Transforming growth factor-alpha. Biochem. Soc. Trans. 19, 259-262.
178. Paul, W.E. and Seder, R.A. (1994). Lymphocyte responses and cytokines. Cell 76, 241.
179. Pennica, D., Shaw, K.J., Swanson, T.A., Moore, M.W., Shelton, D.L., Zioncheck, K.A., Rosenthal, A., Taga, T., Paoni, N.F. and Wood, W.I. (1995). Cardiotrophin-1: Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270, 10915.
180. Perkins, J.D., Nelson, D.L., Rakela, J., Grambsch, P.M. and Krom, R.A. (1989). Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 47, 77.
181. Pernis, A., Gupta, S., Yopp, J., Garfein, E., Kashleva, C.S., Schindler, C. and Rothman, P. (1995). γ chain-associated cytokine receptors signal through distinct transducing factors. J. Biol. Chem. 270, 14517-14522.
182. Pfeffer, K., Matsuyama, T., Kundig, T., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P., Kronke, M. and Mak, T. (1993). Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 73, 457-467.
183. Plaut, M., Pierce, J.H., Watson, C.J., Hanley-Hyde, J., Nordan, R.P. and Paul, W.E. (1989). Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores. Nature 339, 64-67.
184. Porteu, F., Brockhaus, M., Wallach, D., Engelmann, H. and Nathan, C. (1991). Human neutrophil elastase releases a ligand binding fragment from the 75kDa tumour necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J. Biol. Chem. 266, 18846.
185. Pousset, F. (1994). Cytokines as mediators in the central nervous system. Biomed. Pharmacother. 48, 425-431.
186. Prieur, A.M., Kaufmann, M.T., Griscelli, C. and Dayer, J.M. (1987). Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet II, 1240.
187. Prince, H.E., Kleinman, S. and Williams, A.E. (1988). Soluble-IL2 receptors levels in serum from blood donors seropositive for HIV. J. Immunol. 140, 1139.
188. Probert, L., Plows, D., Kontogeorgos, G. and Kollias, G. (1995), The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25, 1794.
189. Pujade-Lauraine, E., Guastalla, J.P., Colombo, N., Devilier, P., Frangois, E., Fumoleau, P., Monnier, A., Nooy, M., Mignot, L., Bugat, R., Marques, C., Mousseau, M., Netter, G., Maloisel, F., Larbaoui, S. and Brandely, M. (1996). Intraperitoneal recombinant Interferon gamma in ovarian cancer with residual disease at second look laparatomy. J. Clin. Oncol. 14, 343-350.
190. Raitano, A.B. and Korc, M. (1993). Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of gamma-interferon receptors. Cancer Res. 53, 636-640.
191. Rankin, E. C., Choy, E. H., Kassimos, D., Kingsley, G. H., Sopwith, A. M., Isenberg, D. A. and Panayi, G. S. (1995). The therapeutic effects of an engineered human antitumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334-342.
192. Ravetch, J.V. and Kinet, J.P. (1991). Fc receptors. Annu. Rev. Immunol. 9, 457-492.
193. Ravoet, C., DeGreve, J., Vandewoude, K., Kerger, J., Sculier, J.P., Lacor, P., Stryckmans, P. and Piccart, M. (1994). Tumour stimulating effects of recombinant human interleukin 6. Lancet 344, 1576-1577.
194. Ray, C., Black, R.A., Kronheim, S.R., Greenstreet, T.A., Sleath, P.R., Salvesen, G.S. and Pickup, D.J. (1992). Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 69, 597-604.
195. Reiner, S.L., Wang, Z.E., Hatam, F., Scott, P. and Locksley, R.M. (1993). TH1 and TH2 cell antigen receptors in experimental leishmaniasis. Science 259, 1457-1460.
196. Renauld, J.C., van der Lugt, N., Vink, A., van Roon, M., Godfraind, C., Warnier, G., Merz, H., Feller, A., Berns, A. and van Snick, J. (1994). Thymic lymphomas in interleukin-9 transgenic mice. Oncogene 9, 1327.
197. Rich, B. E., Campos-Torres, J., Tepper, R., Moreadith, R. and Leder, P. (1993). Cutaneous lymphoproliferation and lymphomas in interleukin transgenic mice. J. Exp. Med. 177, 305.
198. Rich, B.E. and Leder, P. (1995). Transgenic expression of interleukin-7 restores T cell populations in nude mice. J. Exp. Med. 181, 1223.
199. Richards, J.M., Mehta, N., Ramming, K. and Skosey, P. (1992). Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 10, 1338-1343.
200. Romagnani, S. (1994). Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12, 227-257.
201. Rosenberg, S.A. (1992). The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180.
202. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., Seipp, C.A., Simpson, C. and Richert, C.M. (1985). Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med. 313, 1485.
203. Rosenberg, S.A., Lötze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Lineham, W.M., Robertson, C.N., Lee, R.S., Rubin, J.T., Seipp, C.A., Simpson, C.G. and White, D.E. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
204. Roth, C., Mir, L.M., Cressent, M., Quintin-Colonna, F., Belehradek, J., Ley, V., Fradelizi, D. and Kourilsky, P. (1992). Inhibition de la croissance tumorale induite par l'injection de cellules histo-incompatibles produisant de l'interleukine 2. Cr. Acad. Sci. Paris 314 Série III, 499.
205. Roux-Lombard, P., Modoux, C., Visher, T., Grassi, J. and Dayer, J.M. (1992). Inhibitors of interleukin-1 activity in synovial fluids and in cultured synovial fluid mononuelear cells. J. Rheumatol. 19, 517.
206. Royall, J.A., Berkow, R.L., Bechman, J.S., Cunningham, M.K., Matalon, S. and Freeman, B.A. (1989). Tumor necrosis factor and interleukin-1 α increase vascular endothelial permeability. Am. J. Physiol. 257, L399-L410.
207. Ruddle, N.H. and Waksman, B.H. (1968). Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon. J. Exp. Med. 128, 1237-1254.
208. Sadlack, B., Kuhn, R., Schorle, H., Rajewsky, K., Muller, W. and Horak, I. (1994). Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur. J. Immunol. 24, 281-284.
209. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C. and Horack, I. (1993). Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253.
210. Sato, T., Widmer, M.B., Finkelman, H., Madani, H., Jacobs, C.A., Grabstein, K.H. and Maliszewski, C.R. (1993). Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE response in vivo. J. Immunol. 150, 2717.
211. Saurat, J.H., Schifferli, J., Steiger, G., Dayer, J.M. and Didierijean, L. (1991). Anti-interleukin-1α autoantibodies in humans: characterization, isotype distribution and receptor binding inhibition. Higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia). J. Allergy Clin. Immunol. 88, 244.
212. Savino, R., Lahm, A., Salvati, A.L., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C. and Ciliberto, G. (1994). Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. Embo. J. 13, 1357.
213. Scambia, G., Testa, U., Panici, P.B., Martcucci, R., Foti, E., Petrini, M., Amoroso, M., Masciullo, V., Peschle, C. and Mancuso, S. (1994). Interleukin 6 serum levels in patients with gynecological tumors. Int. J. Cancer. 57, 318.
214. Schall, T.J. (1991). Biology of the RANTES/SIS cytokine family. Cytokine 3, 165-183.
215. Schmidt-Wolf, G.D. and Schmidt-Wolf Ingo, G.H. (1995). Cytokines and gene therapy. Immunol. today 16, 173-175.
216. Schmitz, J., Assenmacher, M. and Radbruch, A. (1992). Induction of cellular immunity: macrophages are the principal antigen presenting cells for TH cells secreting IFN-γ (Th1 cells). In New Advances on Cytokines, ed. S. Romagnani, T. R. Mosmann, A. K. Abbas, pp. 131-136.
217. Schoenfeld, H.J., Poeschl, B., Frey, J.R., Loetscher, H., Hunziker, W., Lustig, A. and Zulauf, M. (1991). Efficient purification of recombinant human tumor necrosis factor beta from escherichia coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors. J. Biol. Chem. 266, 3863-3869.
218. Schorle, H., Holtschke, T., Hünig, T., Schimpl, A. and Horak, I. (1991). Development and function of T cells in mice rendered interleukin 2 deficient by gene targeting. Nature 352, 621-624.
219. Seder, R.A., Paul, W.E., Davis, M.M. and Fazekas de St Groth, B. (1992). The presence of interleukin 4 during in vitro priming determines the lymphocyte-producing potential of CD4+ T cells from T cell receptor transgenic mice. J. Exp. Med. 176, 1091-1098.
220. Sideras, P., Noma, T. and Honjo, T. (1988). Structure and function of interleukin 4 and 5. Immunol. Rev. 102.
221. Simpson, W.G., Heys, S.D. and Whiting, P.H. (1995). Acute phase proteins and recombinant IL2 therapy: prediction of response and survival in patients with colorectal cancer. Clin. Exp. Immunol. 99, 143-147.
222. Simpson, M.A., Madras, P.N., Cornaby, A.J., Etienne, T., Dempsey, R.A., Clowes, G.H. and Monaco, A.P. (1989). Sequential determinations of urinary cytology and plasma and urinary lymphockines in the management of renal allograpft recipients. Transplantation 47, 218.
223. Sleijfer, D.Th., Janssen, R.A.J., Buter, J., De Vries, E.G.E. and Willemse, P.H.B. (1992). Phase II study of subcutaneous interleukin 2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 7, 1119-1123.
224. Smith, C.A., Davis, T., Wignall, J.M., Din, W.S., Farrah, T., Upton, C., McFadden, G. and Goodwin, R.G. (1991). T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biomed. Biophys. Res. Commun. 176, 335.
225. Smith, C.A., Davis, T., Anderson, D., Solam, L., Beckmann, M.P., Jerzy, R., Dower, S.K., Cosman, D. and Goodwin, R.G. (1990). A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248, 1019.
226. Smith, C.A., Farrah, T. and Goodwin, R.G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959.
227. Snapper, C.M., Finkelman, F.D. and Paul, W.E. (1988). Regulation of IgG1 and IgE production by interleukin-4. Immunol. Rev. 102, 51-75.
228. Sorg, R.V., Enczmann, J., Sorg, U.R., Schneider, E.M. and Wermel, P. (1993). Identification of an alternatively spliced transcript of human interleukin 4 lacking the sequence encoded by exon 2. Exp. Hematol. 21, 560.
229. Soulillou, J.P., Cantorovich, D. and Le Mauff, B. (1990). Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B 3·1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl. J. Med. 322, 1175.
230. Spriggs, D., Imamura, K., Rodriguez, C., Horiguchi, J. and Kufe, D.W. (1987). Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Nat. Acad Sci. 84, 6563-6566.
231. Suda, T., Takahashi, T., Golstein, P. and Nagata, S. (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169.
232. Suematsu, S., Matsusaka, T., Matsuda, T., Ohno, S., Miyazaki, J.I., Yamamura, K., Hirano, T. and Kishimoto, T. (1992). Generation of plasmocytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Nat. Acad. Sci. 89, 232-235.
233. Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Pallidino, M.A. Jr. and Shepard, H.M. (1985). Recombinant human tumor necrosis factor α effects on proliferation of normal and transformed cells in vitro. Science 230, 943-945.
234. Suter, P.M., Suter, S., Girardin, E., Roux-Lombard, P., Grau, G.E. and Dayer, J.M. (1992). High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon and elastase, in patients with adult respiratory distress syndrome after trauma, shock or sepsis. Am. Rev. Respir. Dis. 145, 1016.
235. Swihart, K., Fruth, U., Messmer, N., Hug, K., Behin, R., Huang, S., Del Giudice, G., Aguet, M. and Louis, J.A. (1995). Mice from a genetically resistant background lacking the interferon γ receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J. Exp. Med. 181, 961.
236. Tadatsugu, T. and Yasuhiro, M. (1993). The IL-2/IL-2 receptor system: a current overview. Cell 73, 5-8.
237. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M. and Sugamura, K. (1992). Cloning of the γ chain of the human IL-2 receptor. Science 257, 379.
238. Takizawa, H., Ohtoshi, T., Ohta, K., Yamashita, N., Hirohata, S., Hirai, K., Hiramatsu, K. and Ito, K. (1993). Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 53, 4175-4181.
239. Tamm, I., Cardinale, L., Krueger, J., Murphy, J.S., May, L.T. and Seligal, P.B. (1989). Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med. 170, 1649-1669.
240. Taniguchi, T. and Minami, Y. (1993). The IL-2/IL-2 receptor system: a current overview. Cell 73, 5.
241. Tartaglia, L.A., Pennica, D. and Goeddel, D.V. (1993). Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TN-F receptor. J. Biol. Chem. 268, 18542.
242. Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.J. and Goeddel, D.V. (1991). The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Nat. Acad. Sci. 88, 9292-9296.
243. Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, L., Pouillart, P. and Fridman, W.H. (1994a). Serum interleukin 6 and C reactive protein levels correlate with resistance to IL2 therapy and poor survival in melanoma patients. Br. J. Cancer. 69, 911-913.
244. Tartour, E., Adams, D., Besancenot, J.F., Fridman, W.H. and Schlumberger, M. (1994b). Poems syndrome with high interleukin (IL) 6 and IL1β serum levels, in a patient with thyroid carcinoma and melanoma. Eur. J. Cancer. 30A, 894-895.
245. Tartour, R., Gey, A., Sastre-Garau, X., Pannetier, C., Mosseri, V., Kourilsky, P. and Fridman, W.H. (1994c). Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res. 54, 6243-6248.
246. Tartour, E., Blay, J.Y., Dorval, T., Escudier, B., Mosseri, V., Douillard, J.Y., Deneux, L., Gorin, I., Negrier, S., Mathiot, C., Pouillart, P. and Fridman, W.H. (1996). Predictors of clinical response to interleukin 2-based immunotherapy in melanoma patients: a french multiinstitutional study. J. Clin. Oncol. 14, 1697-1703.
247. Tartour, R., Lee, R.S. and Fridman, W.H. (1994). Anti-cytokines: promising tools for diagnosis and immunotherapy. Biomed. Pharmacother. 48, 417-424.
248. Tartour, E., Mathiot, C. and Fridman, W.H. (1992). Current status of interleukin 2 therapy in cancer. Biomed. Pharmacother. 46, 473-484.
249. Tartour, E., Pannetier, C., Mathiot, C., Teillaud, J.L., Sautès, C., Kourilsky, P. and Fridman, W.H. (1995). Prognostic value of cytokine and soluble Fcγ receptor assays in oncology. Immunol. Letters 44, 145-148.
250. Thiounn, N., Mathiot, C., Dorval, T., Tartour, R., Mosseri, V., Zerbib, M., Fridman, W.H. and Debre, B. (1995). Lack of efficacy of low dose subcutaneous recombinant interleukin 2 and interferon-α in the treatment of metastatic renal cell carcinoma. Br. J. Urology. 75, 586-589.
251. Thompson, J.A., Peace, D.J., Klarnet, J.P., Kern, D.E., Greenberg, P.D. and Cheever, M.A. (1986). Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J. Immunol. 137, 3675.
252. Tisi, E.R., Lissoni, P. and Angeli, M. (1992). Postoperative increase in soluble interleukin-2 receptor serum levels as a predictor for early recurrence in non small cell lung carcinoma. Cancer 69, 2458.
253. Toi, M., Bicknell, R. and Harris, A.L. (1992). Inhibition of colon and breast carcinoma cell growth by interleukin 4. Cancer Res. 52, 275-279.
254. Topp, M.S., Papadimitriou, C.A., Eitelbach, R., Oelman, E., Koehler, B., Oberberg, D., Von Marschall, Z., Reufl, B., Stein, H. and Thiel, E. (1995). Leuk. Lymph. 19, 319-328.
255. Totpal, K. and Aggarwal, B.B. (1991). Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res. 51, 4266-4270.
256. Tracey, K.J., Beutler, B., Lowry, S.F., Merryweather, J., Wolpe, S., Milsark, I.W., Hariri, R.J., Fahey, T.J., Zentella, A., Albert, J.D., Shires, G.T. and Cerami, A. (1986). Shock and tissue injury induced by recombinant human cachectin. Science 234, 470-474.
257. Trinchieri, G. (1994). Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84, 4008-4027.
258. Trinchieri, G. and Scott, P. (1995). Immunoregulation by interleukin-12. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 146, 423-651.
259. Unterhuber, R. (1993). Gene therapy gaters speed in Germany. Nature 365, 197.
260. Upton, C., Macen, J.L., Schreiber, M. and McFadden, G. (1991). Myxoma virus expresses a secreted protein with homology to the tumour necrosis factor receptor gene family that contributes to viral virulence. Virology 184, 370.
261. Urabe, A. (1994). Interferons for the treatment of hematological malignancies. Oncology 51, 137-141.
262. Van Meir, E., Sawamura, Y., Diserens, A.C., Hamou, M.F. and de Tribolet, N. (1990). Human glioblastoma cells release interleukin 6 in .vivo and in vitro. Cancer Res. 50, 6683-6688.
263. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P. and Fiers, W. (1993). Human TNF mutants with selective activity on the p55 receptor. Nature 361, 266-269.
264. Van Snick, J. (1990). Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253-278.
265. Vidal-Vanaclocha, F., Amézaga, C., Asumendi, A., Kaplanski, G. and Dinarello, C.A. (1994). Interleukin-1 receptor blockade reduces the number and size of murine B 16 melanoma hepatic metastases. Cancer Res. 54, 2667.
266. von Herrath, M.G., Allison, J., Miller, J.F. and Oldstone, M.B. (1995). Focal expression of interleukin-2 does not break unresponsiveness to 'self' (viral) antigen expressed in β cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J. Clin. Invest. 95, 477.
267. Vowels, B.R., Lessin, S.R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J.T. and Rook, A.H. (1994). TH2 cytokine mRNA expression in skin in cutaneous T cell lymphoma. J. Invest Dermatol. 103, 669-673.
268. Walker, N.P.C., Talanian, R.V., Brady, K.D., Dang, L.C., Bump, N.J., Ferenz, C.R., Franklin, S., Ghayur, T., Hackett, M.C., Hamill, L.D., Herzog, L., Hugunin, M., Houy, W., Mankovich, J.A., McGuiness, L., Orlewiez, E., Paskind, M., Pratt, C.A., Reis, P., Summani, A., Terranova, M., Welch, J.P., Xiong, L., Moller, A., Tracey, D.E., Kamen, R. and Wong, W.W. (1994). Crystal structure of the cysteine protease interleukin-10 converting enzyme: a (p20/p10) 2 homodimer. Cell 78, 343-352.
269. Wang, Z.E., Reiner, S.L., Zheng, S., Dalton, D.K. and Locksley, R.M. (1994). CD4+ effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J. Exp. Med. 179, 1367.
270. Weiss, M., Yokoyama, C., Shikama, Y., Naugle, C., Druker, B. and Sieff, C.A. (1993). Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the a and β subunits. Blood 82, 3298.
271. Weissglas, M., Schamhart, D., Lowik, C., Papapoulos, S., Vos, P. and Kurth, K.H. (1995). Hypercalcemia and cosecretion of interleukin 6 and parathyroid hormone related peptide by human renal cell carcinomas implanted into nude mice. J. Urology. 153, 854-857.
272. Welch, D.R., Fabra, A. and Nakajima, M. (1990). Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Nat. Acad. Sci. 87, 7678-7682.
273. Whaley, K. (1987) ed. Complement in Health and Disease. Lancaster, UK: MTP Press.
274. Wigginton, J.M., Komschlies, K.L., Back, T.C., Franco, J.L., Brunda, M.J. and Wiltrout, R.H. (1996). Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Nat. Cancer. Inst. 88, 38-43.
275. Wijdenes, J., Heinrich, P.C., Muller-Newen, G., Roche, C., Gu, Z.J., Clement, C. and Klein, B. (1995). Interleukin 6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Immunol. 25, 3474-3481.
276. Williams, M.E., Chang, T.L., Burke, S.K., Lichtman, A.H. and Abbas, A.K. (1991). Activation of functionally distinct subsets of CD4+ T lymphocytes. Res. Immunol. 142, 23-27.
277. Williams, M.E., Lichtman, A.H. and Abbas, A.K. (1990). Anti-CD3 antibody induces unresponsiveness to IL-2 in TH1 clones but not in Th2 clones. J. Immunol. 144, 1208-1214.
278. Williams, R.O., Williams, D.G. and Feldmann, M. (1990). Anti-TNF treatment reduces the severity of murine collagen induced arthritis. Clin. Rheumatol. 9, 565.
279. Wolf, S.F., Temple, P.A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Azzoni, L., Chan, S.H., Trinchieri, G. and Perussia, B. (1991). Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killers cells. J. Immunol. 146, 3074.
280. Woodworth, C.D., McMullin, E., Iglesias, M. and Plowman, G.D. (1995). Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Nat. Acad. Sci. 92, 2840-2844.
281. Wooley, P.H., Dutcher, J., Widmer, M.B. and Gillis, S. (1993). Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151, 6602-6607.
282. Wu, S., Rodabaugh, K., Martinez-Maza, O., Watson, J.M., Silverstein, D.S., Boyer, C.M., Peters, W.P., Weinberg, B., Berek, J.S. and Bast, R.C. Jr. (1992). Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin 1, interleukin 6 and tumor necrosis factor a. Am. J. Obst. Gynecol. 166, 997-1007.
283. Yamamura, M., Modlin, R.L., Ohmen, J.D. and Moy, R.L. (1993). Local expression of anti-inflammatory cytokines in cancer. J. Clin. Invest. 91, 1005.
284. Yoneda, T., Alsina, M.M., Chavez, J.B., Bonewald, L., Nishimura, R. and Mundy, G.R. (1991). Evidence that splenic tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia and leukocytosis in a human tumor in nude mice. J. Clin. Invest. 87, 977-985.
285. Yoneda, T., Nakai, M., Moriyama, K., Scott, L., Ida, N., Kunitomo, T. and Mundy, G.R. (1993). Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 53, 737-740.